Clinical Trial Update: Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression [Phase 1, Phase 2]

View source ↗

Summary

AstraZeneca is evaluating AZD3632 as monotherapy or with other anticancer agents in adults with advanced hematologic malignancies associated with HOX overexpres…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• AZD3632

Snippet

Sponsor: AstraZeneca | Conditions: Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia | Phase 1, Phase 2 | Status: RECRUITING